Login
Humacyte, Inc. logo

Humacyte, Inc.

humacyte.com

What Do They Do?

Manufactures and sells Symvess, a bioengineered blood vessel, and develops other engineered tissues for hospitals, trauma centers and outpatient surgical settings.

How Do They Make Money?

revenue
SegmentShareRevenue
Product
68%
Contract Revenue
32%

Who Are Their Customers?

Humacyte reaches U.S. trauma centers through its own sales and marketing team and is pursuing partners with established distribution channels for specialized markets.

Do Revenues Turn Into Profits?

No. It lost $40.8M in FY2025.

Operating income, FY2025
−5306% of revenue
▲ +5% (Loss) vs FY2024 (−$114.4M)
Net income, FY2025
−2004% of revenue
▲ +73% (Loss) vs FY2024 (−$148.7M)
Free cash flow, FY2025
−5198% of revenue
▼ −6% (Loss) vs FY2024 (−$99.7M)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +37%
vs $753K in Q3 FY2025
Net income
▲ +11% (Loss)
vs −$17.5M in Q3 FY2025
Product share of revenue vs 93.4% in Q3 FY2025
  • Nov 10, 2026 Humacyte expects fourth-quarter Symvess sales to at least double October sales were $0.8 million, and fourth-quarter sales were expected to at least double the third quarter's $1.0 million.
  • Jul 31, 2026 Nasdaq notified Humacyte of a minimum bid-price deficiency Its listing continued while it had until January 27, 2027, to meet the $1.00 minimum for 10 consecutive business days.
  • Apr 21, 2026 Humacyte regained worldwide commercialization rights to its vessel It will pay Fresenius royalties on sales outside the U.S.; U.S. royalty terms remain in place.

Growing. Revenue grew 61% in 4 years, from $1.3M in FY2021 to $2M in FY2025, about 13% a year.

Commercial launch The older report described the vessels as investigational, while the latest report says Symvess received U.S. Food and Drug Administration approval and commercial sales began in the United States.

Revenue over time
Product Contract Revenue
$2.5M$1.3M$0

Who Do They Compete With?

Competes with Bard Peripheral Vascular, W.L. Gore & Associates, Terumo Medical Systems, and Atrium

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support